Search
Immunocore Holdings PLC
IMCRAdd to Watchlist
32.540USD
+0.890+2.81%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.66BMarket Cap
LossP/E TTM
More Details of Immunocore Holdings PLC Company
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a pipeline of clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, ovarian, lung, colorectal and others.
Immunocore Holdings PLC Info
Ticker SymbolIMCR
Company nameImmunocore Holdings PLC
IPO dateFeb 05, 2021
CEOJallal (Bahija)
Number of employees493
Security typeDepository Receipt
Fiscal year-endFeb 05
Address92 Park Drive Milton Park
CityABINGDON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited Kingdom
Postal codeOX14 4RY
Phone441235438600
Websitehttps://www.immunocore.com/
Ticker SymbolIMCR
IPO dateFeb 05, 2021
CEOJallal (Bahija)
Company Executives of Immunocore Holdings PLC
Name
Name/Position
Position
Shareholding
Change
Prof. John Bell
Prof. John Bell
Independent Chairman of the Board
Independent Chairman of the Board
13.45K
--
Dr. Bahija Jallal, Ph.D.
Dr. Bahija Jallal, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
12.34K
--
Dr. David Berman, M.D., Ph.D.
Dr. David Berman, M.D., Ph.D.
Head of Research and Development
Head of Research and Development
--
--
Mr. Travis Coy
Mr. Travis Coy
Chief Financial Officer and Head of Corporate Development
Chief Financial Officer and Head of Corporate Development
--
--
Mr. Roy S. Herbst, M.D., Ph.D.
Mr. Roy S. Herbst, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Kristine Peterson
Ms. Kristine Peterson
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Prof. Peter Ratcliffe
Prof. Peter Ratcliffe
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Clayton Robertson
Mr. Clayton Robertson
Head of Investor Relations
Head of Investor Relations
--
--
Mr. Siddharth Kaul
Mr. Siddharth Kaul
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. William Pao, M.D., Ph.D.
Dr. William Pao, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Prof. John Bell
Prof. John Bell
Independent Chairman of the Board
Independent Chairman of the Board
13.45K
--
Dr. Bahija Jallal, Ph.D.
Dr. Bahija Jallal, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
12.34K
--
Dr. David Berman, M.D., Ph.D.
Dr. David Berman, M.D., Ph.D.
Head of Research and Development
Head of Research and Development
--
--
Mr. Travis Coy
Mr. Travis Coy
Chief Financial Officer and Head of Corporate Development
Chief Financial Officer and Head of Corporate Development
--
--
Mr. Roy S. Herbst, M.D., Ph.D.
Mr. Roy S. Herbst, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Kristine Peterson
Ms. Kristine Peterson
Non-Executive Independent Director
Non-Executive Independent Director
--
--
FAQs
Who are the top five shareholders of Immunocore Holdings PLC?
The top five shareholders of Immunocore Holdings PLC are: Prof. John Bell
How many institutions hold shares of Immunocore Holdings PLC (IMCR)?
As of 2026Q1, 320 institutions hold shares of Immunocore Holdings PLC, with a combined market value of approximately 49.60M, accounting for 97.50% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -9831616.00.